HALO
NASDAQHalozyme Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks64-89%
2025-12-142026-06-07
Mix3290d
- Insider15(47%)
- SEC Filings9(28%)
- Other4(13%)
- Leadership2(6%)
- Earnings2(6%)
Latest news
25 items- INSIDERPRESIDENT AND CEO Torley Helen sold $3,370,008 worth of shares (50,000 units at $67.40) as part of a pre-agreed trading plan and exercised 50,000 shares at a strike of $12.07 (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Connaughton Bernadette sold $107,591 worth of shares (1,625 units at $66.21) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 43,669 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERPRESIDENT AND CEO Torley Helen exercised 50,000 shares at a strike of $12.07 and sold $3,433,875 worth of shares (50,000 units at $68.68) as part of a pre-agreed trading plan (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECSEC Form 10-Q filed by Halozyme Therapeutics Inc.10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCEAnnouncing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in 2026Total Revenue Increased 42% YOY to $377 millionRoyalty Revenue Increased 43% YOY to $241 millionReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%Royalty Revenue of $1.130 - $1.170 billion, YOY Growth of 30% - 35%Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1SAN DIEGO, May 11, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March
- INSIDERDirector Posard Matthew L. was granted 3,796 shares, increasing direct ownership by 5% to 77,835 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Krishnan Mahesh was granted 3,796 shares, increasing direct ownership by 36% to 14,462 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Lang James Paul was granted 3,796 shares, increasing direct ownership by 427% to 4,685 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Henderson Jeffrey William was granted 3,796 shares, increasing direct ownership by 12% to 36,572 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Duncan Barbara Gayle was granted 3,796 shares, increasing direct ownership by 19% to 23,715 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Connaughton Bernadette was granted 6,796 shares, increasing direct ownership by 18% to 45,294 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHalozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology TargetsMarks first ENHANZE® agreement to include ADC targetsCollaboration also includes option for additional future targetsFirst clinical trial projected to initiate in 2026SAN DIEGO, May 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK. Under the collaboration, GSK has licensed Halozyme's ENHANZE® drug delivery technology for the development and potential commercialization of subcutaneous administration of multiple oncology targets, including antibody drug conjugates (ADCs), as well as an option for additional future drug targets."We are excited to work wit
- PRHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyAgreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional targetSAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and Oruka Therapeutics, Inc. (NASDAQ:ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.Under the agreement, Oruka has licensed Halozyme's Hypercon™ technology for use with ORKA‑001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon™ is an innovative microparticle technology that allows for
- INSIDERDirector Connaughton Bernadette sold $103,155 worth of shares (1,625 units at $63.48) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 38,498 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECSEC Form 144 filed by Halozyme Therapeutics Inc.144 - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)
- PRHalozyme to Report First Quarter 2026 Financial and Operating ResultsSAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May 11, 2026, following the close of trading.Halozyme will host a conference call on Monday, May 11, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/178516398?pwd=q41k1S5tA live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.About HalozymeHalozyme is a biopharmaceutical company advancing
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHalozyme Appoints Darren Snellgrove as Chief Financial OfficerSAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026.Mr. Snellgrove will be responsible for leading Halozyme's financial operations and strategy, including capital allocation, corporate development and investor relations. Darren will report to Helen Torley, President and Chief Executive Officer."I am delighted to have a financial leader of Darren's experience and caliber join Halozyme at this exciting time. He is a highly respected finance leader with deep experience and an expansive skillset, demonstrated by successful leadershi
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- INSIDERSEC Form 4 filed by Torley Helen4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRHalozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ TechnologySAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated ("Vertex"). Under the collaboration, Vertex has licensed Halozyme's Hypercon™ technology for use in up to three drug targets. Hypercon™ is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration."This collaboration with Vertex underscores the versatility and potentia
- INSIDERSEC Form 4 filed by Ramsay David A4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERSEC Form 4 filed by Torley Helen4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
HALO FAQ
6 questionsWhat does Halozyme Therapeutics Inc. do?
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for...Where does HALO stock trade?
Halozyme Therapeutics Inc. (HALO) is listed on NASDAQ.What sector and industry is HALO in?
Halozyme Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about HALO?
Halozyme Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Sell on 2025-12-04. Recent price targets cluster around $4700.00.What companies are similar to HALO?
Notable peers in the same industry include TPTX (Turning Point Therapeutics Inc.), CBAY (CymaBay Therapeutics Inc.), CDTX (Cidara Therapeutics Inc.). Compare HALO side-by-side with any of them on Quantisnow.How can I track HALO on Quantisnow?
Quantisnow aggregates Halozyme Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HALO to receive live email and push alerts on every new disclosure.